MIR Kevin Bowles and Rob Hallford, Director of Duke New Ventures chat at I&E’s Bullpen – the hub for all innovation and entrepreneurship activity at Duke University.

Successful 1st Year for New Ventures’ MIR Program

OLV’s Mentors-in-Residence (MIR) program didn’t reinvent the start-up/entrepreneurial wheel — rather, just enabled it to turn faster and more efficiently, heading toward the path to greater success.

New Ventures logo

And since its creation just a short year ago, the MIRs have helped Duke New Ventures advance many new start-ups into the marketplace.  New Ventures is the starting point for turning a university-developed idea into a start-up company.  The center helps inventors think through opportunities, craft business plans and investment pitches, find funding and establish industry contacts.

MIR Fred Kornahrens chats with Joe Knight, CEO of InnAVasc Medical, Inc. a medical device company founded by Duke University surgeons and scientists, which designs and develops products for vascular access for hemodialysis.
MIR Fred Kornahrens chats with Joe Knight, CEO of InnAVasc Medical, Inc. a medical device company founded by Duke University surgeons and scientists, which designs and develops products for vascular access for hemodialysis.

Under Rob Hallford, Duke New Ventures developed several new strategies to vet faculty and staff inventions and support their development into spinoff companies.  One of those new strategies was hiring five MIRs—seasoned entrepreneurs who have successfully raised capital for, built, sold, or invested in start-up companies.

“What we’ve recruited for in our MIRs is a diverse set of experiences and expertise to help our faculty across multiple technology and industry sectors.  But more than that, we’ve been able to find entrepreneurs with an energy for engaging with and building out Duke’s entrepreneurial community,Hallford said.

The main focus of Duke New Ventures is on finding commercial channels and good management for these Duke innovations. However, much of the work is about building relationships.

MIRs have spent their careers building deep industry relationships. As such, they are matched with innovators within the same industry to help them move their ideas to the market.  An MIR not only helps the faculty or staff member develop their company plan such that introductions can be made to potential investors, management and partners, but they also help cultivate those connections.

“As a clinician and scientist, I’m adept at thinking about how products we develop may fit in the lives of patients and their caregivers.  But an important gap in my knowledge and comfort is understanding product/market fit from a business development perspective,” said Arif Kamal, Associate Professor of Medicine and co-founder of the mobile health platform Prepped Health.

MIR Kevin Bowles and Rob Hallford, Director of Duke New Ventures chat at I&E’s Bullpen – the hub for all innovation and entrepreneurship activity at Duke University.
MIR Kevin Bowles and Rob Hallford, Director of Duke New Ventures chat at I&E’s Bullpen – the hub for all innovation and entrepreneurship activity at Duke University.

Kamal was paired with MIR Kevin Bowles, who has over 25 years of entrepreneurial experience. “Kevin has been an invaluable resource in pressure testing our ideas before we head to market.  He is supportive and yet pushes back when needed, so that ultimately, we come to market with the best plan.  He is equal parts cheerleader and coach.”

Tech-transfer opportunities are increasingly important to faculty and staff. By tapping into these experienced entrepreneurs’ business and networking expertise, New Ventures aims to not only promote technology translation but also enable Duke inventors to have a better understanding of the business value proposition.

MIR Fred Kornahrens, who has supported over a dozen pioneering researchers this past year, saw this within the projects he mentored, “I witnessed significant enlightenment on the part of the innovators as to the true meaning of a value proposition for their technology.  Moving from a lack of understanding and the need for it to fully developing and embracing it.”

This last year saw the New Ventures team make 89 introductions and nurture numerous startup ventures based on Duke faculty/staff technologies, with 1 company acquired for $33 million.  15 of 16 start-ups formed in FY18 have stayed in the Durham/Triangle area, providing jobs and contributing to the thriving local economy.

In conjunction with OLV and through their own efforts, Duke start-ups have raised over $525 million this year.

Patient being scanned in tunnel

Polarean Imaging Enrolled 1st Patient in Clinical Trials

Polarean Imaging, a medical imaging technology company enrolled their first patient in its Phase III FDA clinical trial.  Polarean designs and manufactures equipment for production of hyperpolarized xenon or helium gas. They have developed a system that can better spot the early signs of chronic obstructive pulmonary disease (COPD).

Polarean logo

The goal of the clinical trial is to perform a non-inferiority study of its drug-device combination using hyperpolarised 129-Xenon (129Xe) gas MRI, against 133-Xenon (133Xe) scintigraphy. The theory is that this method is more accurate and less harmful than current methods. They will be evaluating a total of 80 patients with lung lobe resection and lung transplant procedures. The Phase III trial will be conducted at Duke University and the University of Virginia.

When used in conjunction with MRI, these gases offer a fundamentally new and non-invasive functional imaging platform. Additionally, xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

Polarean, spun out of Dr. Bastiann Driehuys and Gary Cofer’s technology from the School of Medicine, launched their start-up in 2014.

John Oxaal

Pratt’s 1st Entrepreneur in Residence

Google ‘Entrepreneur in Residence (EIR)’ and you will get a varied set of skill requirements with phases like venture capital, startups, seed funding, spin-offs, and so on.

As a venture capitalist, the objective is to look at deals that come their way and make a determination as to the strength of the technology and management team.  If they like the idea and managers, it’s a good indicator towards investment.

However, for an EIR this notion is flip-flopped—they already like the tech and the team; it’s more about choosing the right investment vehicle.

For Pratt’s Biomedical Engineering (BME) Chair Ashutosh Chilkoti asking a former BME graduate, John Oxaal, to become Pratt’s first EIR was an easy choice. With an undergraduate degree in BME from Duke, an MBA from the University of Chicago, and experience as both an entrepreneur and a venture capitalist, he had the perfect skillset to help catalyze new startups around BME technologies.

John Oxaal

In the early 90s, Oxaal worked with Professor Olaf von Ram to help form Volumetrics Medical Imaging, which developed the first real-time 3-D ultrasound machine. Oxaal stayed with Volumetrics until ’99 before moving to the west coast to work at Sevin Rosen Funds as a venture capitalist.

“I knew John would be an excellent candidate to help expand BME’s knowledge and technology,” Chilkoti said. “As a Duke BME alum, and with previous Duke start-up experience, I knew he could guide us through the process of transferring BME’s innovative research to the market.”

Soon after taking on his position as an EIR, Oxaal landed on the gene editing research of Professor Charles Gersbach and his colleagues Greg Crawford, Tim Reddy, and Kris Wood.

In 2015, through his role as the Duke BME EIR, Oxaal helped Gersbach, et al. found Element Genomics, a Duke startup developing a suite of technologies for understanding gene regulatory elements, such as CRISPR gene editing technologies, to identify new drug targets for common diseases. Oxaal would later become the CEO of Element.

Charles Gersbach
Professor Charles Gersbach, Pratt BME

“As academics interested in translating our work to the biotech industry, it was critical to have a veteran entrepreneur like John to guide us through the unfamiliar territory of founding a company, licensing technology, and setting up operations outside of a university,” Professor Gersbach said of Pratt’s EIR. “Another critical factor to making this all possible was the incredible responsiveness we received from Duke’s OLV. They were diligent in every step of the process from protecting and managing the IP to participating in final license and contract discussions.”

The Element founders also received funding from the Coulter Foundation Translational Partnership Program at Duke that provides $1 million in early-stage funding and management to faculty health care innovations annually with a goal of licensing and creating new life science start-up companies.

The Coulter Foundation is directed by veteran entrepreneur Professor Barry Myers. Myers saw much potential in the Element team and pushed hard to get them to move forward with their idea.

Now the company has moved on to further success with the acquisition announcement this month by UCB, a global biopharmaceutical company based in Belgium with a clinical development office in Raleigh.

“We at Element are thrilled that UCB shared our vision for treating disease through knowledge gained through functional genomics and the vast and largely unexplored biology of the epigenome.  We believe that together with UCB we can much more quickly harness the power of this approach”, Oxaal said. “Duke’s emphasis on entrepreneurship and engagement with industry has paved the way towards research that can powerfully inform today’s drug development process.”

The Element team will continue to work in Durham closely with UCB’s genomics research arm employing eight Duke graduated students and continuing its collaboration with the Gersbach, Reddy, Crawford, and Wood labs at Duke.

ucb logo
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases.

“Duke has made a significant commitment to improving its tech transfer function and assistance to our startup companies; therefore, we are especially pleased to see these types of successes,” said Robin Rasor, Executive Director of Duke’s Office of Licensing & Ventures (OLV).

On the back of this success, BME and OLV have combined their efforts to make use of OLV’s Mentor-in-Residence (MIR) program, which work under the recently formed Duke New Ventures.

Duke New Ventures Logo“It is only fitting,” said Rasor, “that OLV and BME have partnered together in the EIR and MIR programs, given that BME is one of the preeminent entrepreneurial department at Duke.”

“With Robin Rasor at the helm,” said Chilkoti, “Duke has new, progressive leadership at OLV, so it was the perfect time for BME to expand our partnership with them. These and other initiatives on campus promise exciting times for faculty entrepreneurs at Duke.”

What’s your next great idea?

Tell OLV or an EIR about it; we can help move it forward.

Suyesh Kunar and other members of the kelaHealth team explain how a group of surgeons, statistician, and engineers have set out to improve surgery outcomes through predictive data analysis.

kēlaHealth Among 6 to Win NC IDEA Grant

In November, a private foundation supporting entrepreneurial innovation North Carolina announced the recipients of the Fall 2017 NC IDEA Seed Grant Awards. These awards total up to $300,000 and Duke start-up kēlaHealth is among the six selected winners to receive a piece of that pie.

Since its inception in 2006, the NC IDEA SEED grant program has awarded over $5 million to 126 companies across the state, with these most recent awards being the 24th cycle of the program.

kelahealth logo

About kēlaHealth

kēlaHealth is a software-as-service health informatics company founded by a team of surgeons, statisticians, and engineers that uses machine learning for predicting complications during surgery. Through rigorous data analysis, kēlaHealth delivers precision medicine by leveraging data from millions of patients, standardizing surgeon variability, and addressing administrative and regulatory needs for quality compliance in surgical care.